Accelovance Expansion Continues with Acquisition of Radiant Development, the CRO Division of Radiant Research

ROCKVILLE, Md., March 6, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc. announced today the acquisition of Radiant Development, the CRO division of Radiant Research. This is the latest development in an expansion strategy by the Maryland based CRO that caters to Biotech and small/mid Pharma Sponsors. Terms of the transaction were not disclosed. 

Accelovance is a patient centric CRO offering innovative solutions to meet the needs of its clients. Much of the company's CRO growth has been in the vaccine, infectious disease, and oncology markets. The addition of Radiant Development broadens Accelovance's ability to provide high quality services across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device.  Radiant Development also has specialized expertise in consumer health and nutrition.

"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company.  Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations," remarked Stephen J. Trevisan, Accelovance President and Chief Executive Officer.

Operating out of locations in Stuart, Florida, Chicago, Illinois, and Durham, North Carolina, Radiant Development has managed over 200 research studies since its inception.  Additionally, the company has established strategic partnerships in Europe and Asia to offer clients global study capabilities.  Radiant Development will operate as a division of Accelovance, providing full service clinical capabilities including: project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.

"With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value to our clients, Radiant Development is delighted to join forces with Accelovance to offer expanded leading edge service solutions to our clients," said Vita Lanoce, Senior Vice President of Development.

Current customers, employees and stake holders of Radiant Development should expect the continued high level of quality, service and performance they are accustomed to receiving.  This includes an ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.     

About Accelovance

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The Company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. Accelovance tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance has a 100% owned subsidiary providing CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at http://www.accelovance.com.  

About Radiant Development

Based in Stuart, Florida, Chicago, Illinois and Durham, North Carolina, Radiant Development is a full service CRO offering clinical development services to the biopharmaceutical, biotech, medical device, nutrition and consumer products industries. Our experienced professionals assess and match client's clinical development needs with the services their program requires for success.  

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
[email protected] 

SOURCE Accelovance